Understanding and controlling inflammation processes has become a central goal in modern medical research. A number of companies developing novel anti-inflammatory drugs has emerged to grow on the wave of recent research findings.
Drug repositioning is a smart and cost-effective approach used by some pharmaceutical companies to re-invent their previously successful drugs in a new role and generate extra value from existing assets.
Pharmaceutical companies find drug repurposing programs largely beneficial over usual drug development from scratch. because they allow saving money on R&D, toxicity tests and other different trials already conducted with a known drug. The risks of failure at a later stage of repurposed drug development are lower, therefore the whole project becomes more attractive from the investor’s point of view.
Integrins are a group of transmembrane receptors playing a major role in cell-cell and cell-extracellular matrix (ECM) interactions. When triggered, integrin receptors transduce signals to the interior of the cell, providing quick and flexible “status update” about chemical composition and mechanical status of the ECM. It results in a cellular response, such as a change in the cell shape, regulation of the cell cycle, adjusting motility, or adding new receptors to the cell membrane.
A billionaire Sean Parker, known as a founder of Facebook and Napster, has steeply entered Life Sciences industry to fund the world’s first-ever CRISPR/Cas9 trial, backed by US federal authorities. Upon success, the probability of which is now hard to assess, this technology can revolutionize the way cancer and many other diseases are treated. This time, Sean Parker is playing a bigger game than ever, however, uncertainty is huge.